1cBio在 BioMarin Pharmaceutical Inc.完成对 Alesta Therapeutics的收购后获得股东收益-动脉网

1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics

CISION 等信源发布 2026-10-14 19:58



可切换为仅中文







ALE1 advanced by 1cBio prior to its worldwide licensing agreement with Alesta Therapeutics

1cBio在与Alesta Therapeutics达成全球许可协议之前推进了ALE1项目

1cBio retains future economic interest in the ALE1 program for hypophosphatasia under the Alesta license agreement assumed by BioMarin

根据BioMarin承接的Alesta许可协议，1cBio保留其在低磷酸酯酶症ALE1项目中的未来经济利益。

SAN FRANCISCO

旧金山

，

Oct. 14, 2026

2026年10月14日

/PRNewswire/ -- 1cBio, a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved diseases including oncology and metabolic disorders, today highlighted BioMarin Pharmaceutical Inc.'s completed acquisition of Alesta Therapeutics, which closed on September 1, 2026, adding Alesta's lead clinical-stage program, ALE1, to BioMarin's pipeline.

/美通社/ -- 专注于为包括肿瘤学和代谢紊乱在内的严重且未被充分满足需求的疾病发现并开发创新疗法的生物制药公司1cBio，今日重点报道了BioMarin Pharmaceutical Inc.已完成对Alesta Therapeutics的收购，该交易于2026年9月1日完成，将Alesta领先的临床阶段项目ALE1纳入BioMarin的产品管线。

ALE1 is a potential first oral therapy for hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene..

ALE1 是低磷酸酯酶症（HPP）的一种潜在首发性口服疗法，低磷酸酯酶症是一种由 ALPL 基因突变引起的罕见遗传性骨病。

继续阅读

ALE1, previously known as OC-1, was advanced by 1cBio prior to its worldwide licensing agreement with Alesta Therapeutics in December 2024. Under that agreement, 1cBio granted Alesta rights to develop and commercialize ALE1 for HPP.

ALE1（此前称为OC-1）由1cBio公司推进研发，直至2024年12月与Alesta Therapeutics达成全球许可协议。根据该协议，1cBio授予Alesta开发并将ALE1用于羟脯氨酸血症（HPP）商业化的权利。

1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics

1cBio在BioMarin Pharmaceutical Inc.收购Alesta Therapeutics交易完成时获得股东收益

Post this

发布此内容

As part of the licensing agreement assumed by BioMarin, 1cBio retains rights to potential development, regulatory and commercial milestone payments, and tiered royalties on global sales.

作为BioMarin承担的许可协议的一部分，1cBio保留获得潜在的开发、监管和商业里程碑付款以及全球销售分级特许权使用费的权利。

'This transaction is an important validation of the scientific insight, early development work, and strategic vision that led 1cBio to pursue ALE1 as a potential oral treatment for people living with hypophosphatasia,' said Andrew Protter, PhD, CEO of 1cBio. 'We are proud to have recognized the potential for this program in HPP, led its maturation into a development-ready asset, and worked closely with Alesta to support its rapid advancement into the clinic.

“此次交易是对1cBio致力于将ALE1开发为低磷酸酯酶症（HPP）患者潜在口服疗法背后的科学洞见、早期开发工作及战略愿景的重要验证。”1cBio首席执行官Andrew Protter博士表示，“我们自豪地识别出该HPP项目的潜力，推动其成长为具备开发条件的资产，并与Alesta密切合作，支持其快速推进至临床研究阶段。”

BioMarin's deep expertise in rare disease and global capabilities make it exceptionally well positioned to advance ALE1's potential for patients with HPP.'.

BioMarin在罕见病领域的深厚专业积累及其全球能力，使其具备独特优势，能够充分推动ALE1为低磷酸酯酶症（HPP）患者带来潜在获益。

Son Pham, Ph.D., Co-founder and Vice President of Chemistry of 1cBio, added, 'Today's announcement underscores the value that can be created through focused drug discovery, thoughtful early development planning, and a strong partnership model. Our early work on ALE1 reflects our expertise in identifying small-molecule approaches for treating underserved conditions.'.

1cBio 联合创始人兼化学副总裁 Son Pham 博士补充道：“今天的公告强调了通过专注的药物发现、深思熟虑的早期开发规划以及强大的合作伙伴模式所创造的价值。我们在 ALE1 上的早期工作反映了我们在识别用于治疗未被充分满足需求疾病的小分子方法方面的专业知识。”

About ALE1

关于 ALE1

ALE1 (OC-1) is an orally active, small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. HPP is a serious condition that can affect bone and tooth mineralization, resulting in easy or frequent bone breaks, early tooth loss, and, in adults, clinically significant muscle weakness, fatigue and pain.

ALE1（OC-1）是一种口服活性小分子药物，有望用于治疗低磷酸酯酶症（HPP）。这是一种由ALPL基因突变引起的罕见遗传性骨病。HPP是一种严重疾病，可影响骨骼和牙齿的矿化，导致易骨折或频繁骨折、牙齿早失，以及在成人中出现具有临床意义的肌无力、疲劳和疼痛。

ALE1 has the potential to be the first oral therapy for HPP that targets the central disease metabolite, PPi (inorganic pyrophosphate), with the potential to impact both skeletal and broader manifestations of HPP through systemic correction of disease biology. In December 2024, 1cBio out-licensed OC-1 to Alesta Therapeutics.

ALE1 有望成为首款针对 HPP 核心疾病代谢物 PPi（无机焦磷酸）的口服疗法，通过系统性地纠正疾病生物学机制， potentially 影响 HPP 的骨骼表现及更广泛的症状。2024 年 12 月，1cBio 将 OC-1 授权给 Alesta Therapeutics。

In August 2026, BioMarin Pharmaceutical, Inc. announced the acquisition of Alesta Therapeutics. ALE1 is currently being evaluated in an ongoing Phase 1/2a clinical trial..

2026年8月，BioMarin Pharmaceutical, Inc.宣布收购Alesta Therapeutics。ALE1目前正在一项正在进行的1/2a期临床试验中接受评估。

About 1cBio

关于 1cBio

1cBio is an emerging biotech company focused on discovering and developing innovative therapies for serious and underserved diseases, with an emphasis on oncology, metabolic disorders, and conditions with limited or inadequate treatment options. The management team brings decades of pharmaceutical industry experience with a proven track record of identifying high-potential targets and rapidly advancing small-molecule programs from discovery to clinical development.

1cBio 是一家新兴的生物技术公司，专注于发现和开发针对严重且治疗需求未得到满足疾病的创新疗法，重点聚焦于肿瘤学、代谢性疾病以及治疗选择有限或不足的疾病领域。管理团队拥有数十年的制药行业经验，在识别高潜力靶点以及快速推动小分子项目从发现阶段进展至临床开发方面有着经证实的卓越记录。

1cBio's initial program is a potential first oral therapy for hypophosphatasia (HPP) in an ongoing Phase 1/2a clinical trial conducted by a development partner. The Company's second program, OC-3, is a potential best-in-class, selective PARP1 inhibitor initially being developed for solid tumors. The Company is based in the San Francisco Bay Area.

1cBio 的首个研发项目是一种潜在的低磷酸酶症（HPP）首创口服疗法，目前正由一家开发合作伙伴开展一项1/2a期临床试验。公司的第二个研发项目 OC-3 是一种潜在的同类最优选择性 PARP1 抑制剂，最初针对实体瘤进行开发。公司总部位于旧金山湾区。

For more information, visit .

更多信息，请访问。

www.1cbio.com

。

Forward Looking Statement

前瞻性陈述

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release other than statements of historical fact, including, without limitation, statements regarding our future results of operations, business strategy, product development, and future market opportunities, are forward-looking statements.

本新闻稿可能包含1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。除历史事实陈述外，本新闻稿中的所有陈述，包括但不限于关于我们未来经营业绩、业务战略、产品开发及未来市场机会的陈述，均为前瞻性陈述。

These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

这些陈述涉及已知和未知的风险、不确定性以及其他因素，这些因素可能导致我们的实际结果、业绩或成就与前瞻性陈述中明示或暗示的任何未来结果、业绩或成就存在重大差异。本发布仅用于提供信息，不构成出售任何证券的要约或购买任何证券的要约邀请。

Any such offer will be made only pursuant to definitive offering documents. Furthermore, this press release contains highly sensitive, proprietary business information and should not be reproduced or distributed to any third party without the express written consent of 1cBio, Inc..

任何此类要约将仅依据最终发行文件进行。此外，本新闻稿包含高度敏感的专有商业信息，未经 1cBio, Inc. 的明确书面同意，不得复制或向任何第三方分发。

Company Contact

公司联系方式

Wilson W. Cheung

张威尔逊

Chief Financial Officer

首席财务官

[email protected]

Investor Contact

投资者联系

Remy Bernarda

雷米·伯纳达